close

Agreements

Date: 2011-04-28

Type of information: Licensing agreement

Compound: two molecules for pain indications

Company: Flamel Technologies (France) Undisclosed specialty pharmaceutical company

Therapeutic area: CNS diseases

Type agreement:

Licensing

Action mechanism:

Disease: pain

Details:

Flamel Technologies has entered into a license agreement with a leading specialty pharmaceutical company for development and commercialization of two molecules for pain indications. The agreement is based on its Micropump® technology.

Financial terms:

Pursuant to the agreement, Flamel will receive an upfront license fee of $3 million, as well as development-based milestones, and mid-single digit royalties upon eventual product sales.

Latest news:

Is general: Yes